#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	13304	16S	1529	1529	99.8	16S.l15.c17.ctg.1	2540	643.6	0	.	n	.	0	A69G	SNP	69	69	A	443	443	G	773	G	773	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	13304	16S	1529	1529	99.8	16S.l15.c17.ctg.1	2540	643.6	0	.	n	.	0	C450T	SNP	450	450	C	824	824	T	864	T	864	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	13304	16S	1529	1529	99.8	16S.l15.c17.ctg.1	2540	643.6	0	.	n	.	0	C1450T	SNP	1450	1450	C	1824	1824	T	821	T,C,G	817,2,2	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	13304	16S	1529	1529	99.8	16S.l15.c17.ctg.1	2540	643.6	1	SNP	n	C1184T	0	.	.	1184	1184	C	1558	1558	C	872	C,T,A	870,1,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	23096	23S	2890	2890	99.93	23S.l6.c30.ctg.1	4063	709.4	0	.	n	.	0	G1337A	SNP	1337	1337	G	1942	1942	A	921	A,G	919,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	23096	23S	2890	2890	99.93	23S.l6.c30.ctg.1	4063	709.4	0	.	n	.	0	T1971C	SNP	1971	1971	T	2576	2576	C	829	C,G,A	827,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	23096	23S	2890	2890	99.93	23S.l6.c30.ctg.1	4063	709.4	1	SNP	n	A2045G	0	.	.	2045	2045	A	2650	2650	A	725	A,C	724,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	23096	23S	2890	2890	99.93	23S.l6.c30.ctg.1	4063	709.4	1	SNP	n	C2597T	0	.	.	2597	2597	C	3202	3202	C	846	C,A,T	844,1,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_Z_01426c	folP.WHO_Z_01426c	1	1	539	1882	folP	852	852	99.88	folP.l15.c4.ctg.1	2066	113.7	0	.	p	.	0	E151K	NONSYN	451	453	GAA	1026	1028	AAA	185;189;188	A,C;A,C;A	184,1;187,1;187	.	.
folP.WHO_Z_01426c	folP.WHO_Z_01426c	1	1	539	1882	folP	852	852	99.88	folP.l15.c4.ctg.1	2066	113.7	1	SNP	p	R228S	1	.	.	682	684	AGC	1257	1259	AGC	211;210;211	A;G;C	210;210;211	folP.WHO_Z_01426c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4654	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3850	150.8	1	SNP	p	S91F	0	.	.	271	273	TCC	840	842	TCC	176;178;174	T;C;C	176;178;174	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4654	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3850	150.8	1	SNP	p	D95G	0	.	.	283	285	GAC	852	854	GAC	188;188;188	G;A,T;C	188;187,1;188	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4654	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3850	150.8	1	SNP	p	D95N	0	.	.	283	285	GAC	852	854	GAC	188;188;188	G;A,T;C	188;187,1;188	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	27	1806	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1814	124.2	1	SNP	p	G45D	0	.	.	133	135	GGC	689	691	GGC	202;199;200	G;G;C	202;199;200	mtrR.WHO_X_01389:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	972	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	1671	72.6	0	.	n	.	0	A197.	DEL	197	197	A	925	925	A	188	A	188	.	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	4250	parC	2304	2304	99.78	parC.l15.c4.ctg.1	3618	146.8	0	.	p	.	0	V435A	NONSYN	1303	1305	GTG	1932	1934	GCA	208;208;208	G;C,T;A	208;207,1;208	.	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	4250	parC	2304	2304	99.78	parC.l15.c4.ctg.1	3618	146.8	1	SNP	p	D86N	0	.	.	256	258	GAC	885	887	GAC	182;180;180	G;A,G,C;C	182;178,1,1;180	parC.WHO_F_01444:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	4250	parC	2304	2304	99.78	parC.l15.c4.ctg.1	3618	146.8	1	SNP	p	S87I	0	.	.	259	261	AGT	888	890	AGT	178;177;178	A;G;T	178;177;178	parC.WHO_F_01444:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	4250	parC	2304	2304	99.78	parC.l15.c4.ctg.1	3618	146.8	1	SNP	p	S87W	0	.	.	259	261	AGT	888	890	AGT	178;177;178	A;G;T	178;177;178	parC.WHO_F_01444:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	4250	parC	2304	2304	99.78	parC.l15.c4.ctg.1	3618	146.8	1	SNP	p	S87R	0	.	.	259	261	AGT	888	890	AGT	178;177;178	A;G;T	178;177;178	parC.WHO_F_01444:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	4250	parC	2304	2304	99.78	parC.l15.c4.ctg.1	3618	146.8	1	SNP	p	S88P	0	.	.	262	264	TCC	891	893	TCC	178;179;184	T;C;C,G	178;179;183,1	parC.WHO_F_01444:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	3984	parE	1986	1986	100.0	parE.l15.c4.ctg.1	3302	150.7	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1805	1807	GGC	213;213;211	G;G;C	213;213;211	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.43.002	penA.43.002	1	1	539	3620	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2994	150.8	0	.	p	.	0	P552L	NONSYN	1654	1656	CCG	2318	2320	CTG	195;197;200	C;T;G	195;197;200	.	.
penA.43.002	penA.43.002	1	1	539	3620	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2994	150.8	1	SNP	p	A311V	0	.	.	931	933	GCA	1595	1597	GCA	195;196;196	G;C;A	195;196;196	penA.43.002:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.43.002	penA.43.002	1	1	539	3620	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2994	150.8	1	SNP	p	I312M	0	.	.	934	936	ATC	1598	1600	ATC	196;195;198	A,C;T,A;C,A	195,1;194,1;197,1	penA.43.002:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.43.002	penA.43.002	1	1	539	3620	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2994	150.8	1	SNP	p	V316P	0	.	.	946	948	GTG	1610	1612	GTG	200;205;206	G,T;T;G	199,1;205;206	penA.43.002:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.43.002	penA.43.002	1	1	539	3620	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2994	150.8	1	SNP	p	V316T	0	.	.	946	948	GTG	1610	1612	GTG	200;205;206	G,T;T;G	199,1;205;206	penA.43.002:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.43.002	penA.43.002	1	1	539	3620	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2994	150.8	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2114	2116	ACC	196;193;194	A;C;C	196;193;194	penA.43.002:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.43.002	penA.43.002	1	1	539	3620	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2994	150.8	1	SNP	p	A502V	1	.	.	1504	1506	GTG	2168	2170	GTG	189;189;186	G;T;G,T	189;189;185,1	penA.43.002:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.43.002	penA.43.002	1	1	539	3620	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2994	150.8	1	SNP	p	V502P	0	.	.	1504	1506	GTG	2168	2170	GTG	189;189;186	G;T;G,T	189;189;185,1	penA.43.002:1:1:V502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.43.002	penA.43.002	1	1	539	3620	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2994	150.8	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2291	2293	GGC	214;213;212	G;G;C	214;213;212	penA.43.002:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.43.002	penA.43.002	1	1	539	3620	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2994	150.8	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2300	2302	GGC	207;207;206	G;G;C	207;207;206	penA.43.002:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	4930	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3524	174.6	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1816	1818	CCG	198;198;192	C;C;G	198;198;192	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2026	porA	1146	1146	99.65	porA.l15.c4.ctg.1	2368	106.9	0	.	p	.	0	M83fs	FSHIFT	247	247	A	882	882	C	146	C	146	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	292	porB1a	984	163	92.64	porB1a.l15.c17.ctg.4	163	49.8	0	.	p	.	0	S271T	NONSYN	811	813	TCG	62	64	ACT	65;65;65	A;C;T	65;65;65	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	292	porB1a	984	163	92.64	porB1a.l15.c17.ctg.4	163	49.8	0	.	p	.	0	Y273D	NONSYN	817	819	TAT	68	70	GAT	65;65;65	G;A;T	65;65;65	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	292	porB1a	984	163	92.64	porB1a.l15.c17.ctg.4	163	49.8	0	.	p	.	0	D274S	NONSYN	820	822	GAT	71	73	AGT	65;65;65	A,T;G,A;T	64,1;64,1;65	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	292	porB1a	984	163	92.64	porB1a.l15.c17.ctg.4	163	49.8	0	.	p	.	0	D276N	NONSYN	826	828	GAT	77	79	AAC	65;65;65	A;A;C,A	65;65;64,1	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	292	porB1a	984	163	92.64	porB1a.l15.c17.ctg.4	163	49.8	0	.	p	.	0	N277H	NONSYN	829	831	AAC	80	82	CAC	65;65;65	C;A;C	65;65;65	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2650	porB1b	1041	1041	96.28	porB1b.l6.c4.ctg.1	2328	142.2	0	.	p	.	0	T89S	NONSYN	265	267	ACC	944	946	AGC	232;229;228	A;G,C,A;C	232;226,2,1;228	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2650	porB1b	1041	1041	96.28	porB1b.l6.c4.ctg.1	2328	142.2	0	.	p	.	0	.	MULTIPLE	358	359	AA	1036	1037	CG	225;224	C;G,A	225;223,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2650	porB1b	1041	1041	96.28	porB1b.l6.c4.ctg.1	2328	142.2	0	.	p	.	0	.	MULTIPLE	361	362	GA	1039	1041	CAG	224;228;227	C;A;G,A	224;228;226,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2650	porB1b	1041	1041	96.28	porB1b.l6.c4.ctg.1	2328	142.2	0	.	p	.	0	N122K	NONSYN	364	366	AAC	1043	1045	AAA	225;226;230	A;A;A,C	225;226;229,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2650	porB1b	1041	1041	96.28	porB1b.l6.c4.ctg.1	2328	142.2	0	.	p	.	0	F131Y	NONSYN	391	393	TTT	1070	1072	TAT	251;253;250	T;A;T	251;253;250	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2650	porB1b	1041	1041	96.28	porB1b.l6.c4.ctg.1	2328	142.2	0	.	p	.	0	N134E	NONSYN	400	402	AAT	1079	1081	GAG	244;244;242	G;A;G	244;244;242	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2650	porB1b	1041	1041	96.28	porB1b.l6.c4.ctg.1	2328	142.2	0	.	p	.	0	V135F	NONSYN	403	405	GTG	1082	1084	TTT	239;241;242	T,A;T;T	238,1;241;242	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2650	porB1b	1041	1041	96.28	porB1b.l6.c4.ctg.1	2328	142.2	0	.	p	.	0	G140K	NONSYN	418	420	GGA	1097	1099	AAA	253;259;256	A,G;A;A	252,1;258;255	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2650	porB1b	1041	1041	96.28	porB1b.l6.c4.ctg.1	2328	142.2	0	.	p	.	0	K143E	NONSYN	427	429	AAA	1106	1108	GAA	248;246;247	G;A,C;A,T,G,C	248;245,1;244,1,1,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2650	porB1b	1041	1041	96.28	porB1b.l6.c4.ctg.1	2328	142.2	0	.	p	.	0	V151A	NONSYN	451	453	GTA	1130	1132	GCA	253;253;252	G;C;A	253;253;252	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2650	porB1b	1041	1041	96.28	porB1b.l6.c4.ctg.1	2328	142.2	0	.	p	.	0	Y212H	NONSYN	634	636	TAT	1313	1315	CAT	238;238;235	C,T;A;T	237,1;238;235	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2650	porB1b	1041	1041	96.28	porB1b.l6.c4.ctg.1	2328	142.2	0	.	p	.	0	T213L	NONSYN	637	639	ACA	1316	1318	TTA	234;232;231	T;T;A	234;232;231	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2650	porB1b	1041	1041	96.28	porB1b.l6.c4.ctg.1	2328	142.2	0	.	p	.	0	A244V	NONSYN	730	732	GCA	1409	1411	GTA	210;211;214	G;T,C;A,G	210;210,1;213,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2650	porB1b	1041	1041	96.28	porB1b.l6.c4.ctg.1	2328	142.2	0	.	p	.	0	G253Q	NONSYN	757	759	GGA	1436	1438	CAA	192;190;192	C;A;A	192;190;191	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2650	porB1b	1041	1041	96.28	porB1b.l6.c4.ctg.1	2328	142.2	0	.	p	.	0	.	INDELS	760	762	ACA	1440	1444	ATCAA	190;189;188;187;188	A;T;C;A;A	189;188;187;186;187	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2650	porB1b	1041	1041	96.28	porB1b.l6.c4.ctg.1	2328	142.2	0	.	p	.	0	.	INDELS	763	764	TG	1447	1449	AGT	189;189;191	A;G;T	188;188;190	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2650	porB1b	1041	1041	96.28	porB1b.l6.c4.ctg.1	2328	142.2	0	.	p	.	0	A257D	NONSYN	769	771	GCT	1454	1456	GAT	186;187;186	G;A;T	186;187;186	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2650	porB1b	1041	1041	96.28	porB1b.l6.c4.ctg.1	2328	142.2	0	.	p	.	0	V270A	NONSYN	808	810	GTA	1493	1495	GCG	194;197;190	G;C;G	194;197;190	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2650	porB1b	1041	1041	96.28	porB1b.l6.c4.ctg.1	2328	142.2	0	.	p	.	0	D293S	NONSYN	877	879	GAT	1562	1564	AGT	200;198;199	A,T;G,A;T	199,1;197,1;199	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2650	porB1b	1041	1041	96.28	porB1b.l6.c4.ctg.1	2328	142.2	1	SNP	p	G120K	1	.	.	358	360	AAG	1036	1038	CGG	225;224;224	C;G,A;G,A	225;223,1;223,1	porB1b.WHO_M_02204c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2650	porB1b	1041	1041	96.28	porB1b.l6.c4.ctg.1	2328	142.2	1	SNP	p	D121N	0	.	.	361	363	GAC	1039	1042	CGC	224;227;227	C;G,A;C	224;226,1;227	porB1b.WHO_M_02204c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2650	porB1b	1041	1041	96.28	porB1b.l6.c4.ctg.1	2328	142.2	1	SNP	p	A121D	1	.	.	361	363	GAC	1039	1042	CGC	224;227;227	C;G,A;C	224;226,1;227	porB1b.WHO_M_02204c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	27	9694	rpoB	4179	4179	100.0	rpoB.l6.c30.ctg.1	5317	227.7	1	SNP	p	H553N	0	.	.	1657	1659	CAT	2239	2241	CAT	235;236;236	C,T;A;T,G	234,1;236;235,1	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1350	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1545	108.8	1	SNP	p	V57M	1	.	.	169	171	ATG	788	790	ATG	246;247;248	A;T;G	246;247;248	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
